Transparency Market Research

Competitive Landscape of Anti-Hypertensive Drugs Market to See Drastic Changes Due to Patent Expiries

Transparency Market Research Report Added "Anti-hypertensive Drugs Market" to its database.


Albany, NY -- (SBWIRE) -- 03/25/2015 -- The demand for anti-hypertensive drugs market is sustainable since hypertension is a lifelong disease. This means a patient will need to take anti-hypertensive drugs every day for the rest of their life. Hypertension is a chronic medical condition, where the arterial blood pressure level gets elevated and reaches an undesired level. Hypertension is also referred commonly as high blood pressure. This condition is measured in terms of systolic and diastolic pressure and treated generally using a combination of anti-hypertensive drugs.

Segmentation of Anti-hypertensive Drugs Market

Anti-hypertensive drugs were noted as the second largest therapy area in the year 2011. The market sale value of anti-hypertensive drugs crossed the US$40 billion mark, according to data from World Preview 2018 report by Evaluate Pharma. The anti-hypertensive drugs market based on their therapeutic class is divided into angiotensin converting enzyme inhibitors (ACE), diuretics, beta blockers, calcium channel blockers, vasodilators, alpha blockers, and renin inhibitors. These anti-hypertensive drugs find their use as a single drug administration or as fixed dose combinations. Diuretics are used to lower blood pressure by increasing urination. Currently, diuretics are used by doctors as the first line of treatment which is recommended by physicians for most of the patients.

Early buyers will receive 10% customization on reports:

Calcium channel blocker helps lower the blood pressure of a patient by decreasing myocardial contractility. ACE inhibitors anti-hypertensive drugs are used to control the patient's level of sodium ions and water in blood which helps to decrease blood pressure. Angiotensin II receptor antagonists have a similar mechanism to that of ACE inhibitors.

Beta-adrenoceptor antagonists are used to lower blood pressure by decreasing the heart rate. Even though diuretics, among all these anti-hypertensive drugs, are used as the first line of treatment by doctors for hypertension, the drug preference also depends upon the medical history of the patient. For example, a hypertensive patient that has diabetes may be prescribed ACE inhibitors as a first line of treatment.

Competitive Landscape of the Global Anti-hypertensive Drugs Market

The global anti-hypertensive drugs market is dominated by six companies that have a stronghold over 70% of the total market share. Currently, Novartis is the market leader with almost 30% of the market share. Novartis is leading the anti-hypertensive drugs market due to its popular drug called Diovan which has contributed to a total of six billion US dollar revenue in the year 2010. Other major products from Novartis available in the anti-hypertensive drugs market include Lotrel, Exforge, Tekturna/Rasilez, and Lescol. The second leading player in the market is Daiichi Sankyo with almost 15% of the market share. The top selling anti-hypertensive drug called Benicar from Daiichi Sankyo is one of the reason making this industry a strong market player.

The third position is held by Sanofi and AstraZeneca with around 20% of market share collectively. The anti-hypertensive drug Atacand from AstraZeneca and Avapro from Sanofi are the reason behind the success of these companies. In the year 2007 and 2010, Pfizer's Norvasc and Merck's Cozaar respectively lost their patents, which have landed these two companies with around 7% market share each. Revatio from Pfizer is one of the top selling drug in the PAH disease market. The company Boehringer Ingelheim also holds a significant share in the anti-hypertensive drugs market with its drug Micardis.

The global anti-hypertensive drugs market will witness many changes in the future related to the market players share. This can be attributed to the fact that the industry will experience in the foreseeable future many patent expiries. Even though, the market scenario in terms of players will show many dynamic changes regarding market share, Novartis will continue to lead the anti-hypertensive drugs market in the coming five years.

More Reports on Pharmaceutical Market :

Enquiry Before Buying :

About Transparency Market Research
TMR's analysts and consultants are distinguished experts in their respective domains. The company is based on an employee-centric model and hires the best, brightest, and most passionate people in the industry. This unparalleled expertise helps TMR uncover latest market intelligence data that's distinct from the competition.

TMR is also a client-centric organization that endeavors to add value to the client's business by delivering the most insightful research. TMR understands that every client has unique product/service offerings, statement, and criteria. Customized solutions from TMR are centered on the client's problem statement. On the other hand, our syndicated research reports provide a packaged solution to keep enterprises abreast of the next major change in their industry.

Transparency Market Research
90 State Street,
Suite 700,
NY - 12207
United States
Tel: 518-618-1030
USA - Canada Toll Free 866-552-3453

Browse Market Research Blog: